-

05:00:28 PM

BRTX Stock News

BRTX - BioRestorative Therapies Inc

06/22/22 7:30 AM

Nasdaq : BRTX

clinical triallow float

BioRestorative Therapies Announces Clinical Trial Contract with Second Site for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)

BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced it has reached an agreement with its second clinical site for its Phase 2 clinical

RHEA-AI

neutral

06/13/22 7:00 AM

Nasdaq : BRTX

clinical triallow float

BioRestorative Therapies Announces Clinical Site Initiation for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)

BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced site initiation for

RHEA-AI

neutral

04/29/22 8:00 AM

Nasdaq : BRTX

clinical triallow float

BioRestorative Therapies Hosts Principal Investigator Meeting for its BRTX-100® Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease

BioRestorative Therapies, Inc. (the “Company” or “ BioRestorative ”) (NASDAQ: BRTX), a clinical stage biopharmaceutical company focused on stem cell-based therapies, today announced that it is hosting a Principal Investigators Meeting in

RHEA-AI

neutral

04/18/22 8:00 AM

Nasdaq : BRTX

clinical triallow float

BioRestorative Therapies Announces Selection of 10 Clinical Sites for its Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease

BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that it has selected 10 of its 15 clinical sites for its Phase 2 clinical trial

RHEA-AI

neutral

04/04/22 8:00 AM

Nasdaq : BRTX

low float

BioRestorative Therapies Announces cGMP Cell Manufacturing Facility Certification

BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today

RHEA-AI

neutral

03/10/22 8:00 AM

Nasdaq : BRTX

low float

BioRestorative Therapies Announces Research Collaboration with Professor Tore Bengtsson to Evaluate Heat Production of its ThermoStem® Program

BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that it has entered into a research collaboration agreement with Dr. Tore Bengtsson,

RHEA-AI

neutral

02/16/22 8:30 AM

Nasdaq : BRTX

low float

BioRestorative Therapies Announces Notice of Allowance on Key Patent for its BRTX-100® Disc Program

BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem

RHEA-AI

neutral

02/07/22 9:00 AM

Nasdaq : BRTX

clinical triallow float

BioRestorative Therapies Announces it has Initiated its Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease – Site Selection Underway

BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (N ASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that it has

RHEA-AI

neutral

02/07/22 7:45 AM

Nasdaq : BRTX

low float

BioRestorative Therapies to Ring Nasdaq Stock Market Closing Bell

BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical-stage company focused on stem cell-based therapies, today announced that Lance Alstodt, BioRestorative’s Chairman and CEO, along with Francisco Silva,

RHEA-AI

neutral

02/02/22 8:00 AM

Nasdaq : BRTX

low float

BioRestorative Therapies Announces Notice of Allowance for New Patent Application in Japan and Expansion of ThermoStem® IP Portfolio

BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a life sciences company focused on stem cell-based therapies, today

RHEA-AI

neutral